Massimiliano Bianchi

Dr. Massimiliano Bianchi is the Founder, President, and Chief Executive Officer of Ulysses Neuroscience Limited. He holds a PhD in Psychopharmacology from the University of Nottingham (UK) and has over 20 years of international R&D and executive experience in neuropharmacology and neuroscience research, including leadership roles in major pharmaceutical companies and CROs such as GlaxoSmithKline (UK), MAPREG (France), and Transpharmation (Ireland).

Before founding Ulysses Neuroscience in 2019, Massimiliano led translational research teams focused on neuronal plasticity and cytoskeletal dynamics in brain disorders. He also holds academic appointments as Adjunct Assistant Professor at Trinity College Dublin and Adjunct Associate Professor at Maynooth University. Under his leadership, Ulysses has become a globally recognized CRO and partner in depression and psychedelics research, supporting biotech and pharmaceutical companies with integrated, biomarker-driven translational platforms that bridge preclinical and clinical development.

In recognition of his entrepreneurial and scientific leadership, Massimiliano received the Campus Company Founders Award in 2023 from Trinity College Dublin, acknowledging Ulysses Neuroscience as a new model in translational neuroscience—operating at the interface between patients, academic research, and the pharmaceutical industry. In 2025, he was also named Champion of Progress by the Loulou Foundation, recognizing his contribution to advancing research and innovation in rare neurodevelopmental disorders.

Massimiliano is an established scientific author with over 50 peer-reviewed publications and is named on multiple patents in the field of neuroscience and drug discovery. His work spans preclinical models, biomarkers, and translational neuroscience strategies that bridge fundamental research and clinical development.